Current and potential pharmacological treatments for obsessive-compulsive disorder

  title={Current and potential pharmacological treatments for obsessive-compulsive disorder},
  author={Joyce D. Davidson and Throstur Bjorgvinsson},
  journal={Expert Opinion on Investigational Drugs},
  pages={1001 - 993}
In the past 20 years, several effective treatments have been developed for obsessive-compulsive disorder. Despite this, it is a disorder that is often inadequately treated by available therapies. Recent advances in neuroimaging and neurophysiology have provided some clues to possible treatments that may be more effective in treating this disorder. Serotonin agents remain the cornerstone of pharmacological treatment for obsessive-compulsive disorder. The development of agents that target… 
Obsessive-compulsive disorder (OCD) is an anxiety disorder characterized by uncontrollable, unwanted thoughts and repetitive, ritualized behaviours that can vary from mild to severe forms.
Glutamatergic dysfunction--newer targets for anti-obsessional drugs.
The rationale for targeting glutamatergic agents as well as the recent important patents for compounds that have emerged from these studies are focused on.
Role of serotonin in obsessive-compulsive disorder
Evidence supporting a role for the serotonin transporter and serotonin receptor subtypes in the pathophysiology and treatment of OCD is summarized.
Obsessive-Compulsive Disorder: Update on Assessment and Treatment
The assessment of OCD can be guided by using published semi-structured interview tools, including a standardized symptom checklist and severity rating scale, and the cognitive-behavioral assessment and treatment approach is provided.


Treatment of severe obsessive-compulsive disorder with fluvoxamine.
Fluvoxamine appears effective in treating severe obsessive-compulsive disorder, as measured by several clinical scales and self-ratings.
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
The results of this preliminary, open-label trial suggest that olanzapine may be effective in augmenting ongoing SSRIs treatment for a portion of patients with obsessive-compulsive disorder refractory to SSRI treatment.
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
Although limited by the retrospective design and lack of controls, these data are consistent with the growing literature suggesting that approximately one-half of OCD patients resistant to treatment with SRIs may respond to augmentation with an atypical antipsychotic.
Open trial of fluoxetine in obsessive-compulsive disorder.
A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive- compulsive symptoms and reinforced the hypothesis of serotonergic abnormalities in obsessive-Compulsive disorder.
Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study
The addition of quetiapine to ongoing SRI therapy has been found to be effective and well-tolerated approach in patients with refractory OCD.
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Improvement in OCD was independent of improvement in mood symptoms and double-blind, placebo-controlled trials are warranted along with trials comparing risperidone and olanzapine augmentation.
Olanzapine Augmentation of Serotonin Uptake Inhibitors in Obsessive—Compulsive Disorder: An Open Study
  • G. Francobandiera
  • Psychology, Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2001
Olanzapine augmentation of SSRIs in treating OCD showed a good response rate, and it could therefore be considered as a treatment option when conventional therapies have failed.
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder, lending partial support to the serotonin hypothesis of OCD.
Risperidone augmentation in refractory obsessivecompulsive disorder: an open-label study:
The addition of risperidone would appear to be a useful strategy for augmenting SRI effectiveness in refractory OCD patients.